Dominic Lunn analyst CREDIT SUISSE

Currently out of the existing stock ratings of Dominic Lunn, 2 are a BUY (100%).

Dominic Lunn

Work Performance Price Targets & Ratings Chart

Analyst Dominic Lunn, currently employed at CREDIT SUISSE,

Wall Street Analyst Dominic Lunn

GSK GlaxoSmithKline PLC ADR NVO Novo Nordisk A/S NVS Novartis AG ADR AZN AstraZeneca PLC ADR SNY Sanofi ADR CM Canadian Imperial Bank Of Commerce MOLN Molecular Partners AG ADR

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 24-Jul-2026

3 months 29 days ago
(24-Jul-2026)

2/3 (66.67%)

$-11.56 (-35.98%)

4036

Buy Since 02-Jul-2024

$67.1

$19.34 (40.49%)

7 months 8 days ago
(14-Apr-2026)

6/7 (85.71%)

$8.98 (15.45%)

454

Hold Since 02-Sep-2025

$70

$22.24 (46.57%)

$45

9 months 13 days ago
(09-Feb-2026)

3/4 (75%)

$12.51 (21.76%)

1662

Hold Since 04-Jan-2022

10 months 16 days ago
(06-Jan-2026)

0/2 (0%)

$-12.1 (-34.00%)

Buy Since 30-Oct-2025

$53

$40

1 years 23 days ago
(30-Oct-2025)

2/2 (100%)

$7.67 (16.92%)

112

Show more analysts

Stocks Dominic Lunn covered previously. Scores are shown for active stocks only.

AZN AstraZeneca PLC ADR CM Canadian Imperial Bank Of Commerce GSK GlaxoSmithKline PLC ADR MOLN Molecular Partners AG ADR NVO Novo Nordisk A/S NVS Novartis AG ADR SNY Sanofi ADR

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Dominic Lunn?

On 2021
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?